All In Biotech

Drug Trial Radar · NCT06211023

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

An Open-label, Randomized, Controlled, Phase II/III Study of SHR-A1921 With or Without Carboplatin Verus Investigator's Choice of Platinum-based Doublet Chemotherapy in Patients With Recurrent Epithelial Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

520

Planned (sponsor's estimate)

Start

Feb 15, 2024

Primary completion

Jun 15, 2026

Study completion Jun 15, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of SHR-A1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • SHR-1921Drug

    SHR-1921

  • carboplatinDrug

    carboplatin AUC 4

  • carboplatinDrug

    carboplatin AUC 5

  • platinum-based doublet chemotherapyDrug

    platinum-based doublet chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate Assessed by Investigator According to RECIST v1.1Time frame: Screening up to study completion, an average of 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.